Ingredient news
Creatine Review Calls for More Detail on Brain Bioavailability
By Nutranexa News |
NutraIngredients reported a review highlighting gaps in how creatine preparations and brain-targeted bioavailability are described in the evidence base.
What Was Reported
NutraIngredients reported that new creatine research highlighted limitations in the detail available on bioavailability and preparations intended for brain-related applications. The report did not present the review as evidence for phosphatidylserine.
For ingredient buyers, the operational message is to compare the exact form, dose, matrix, study population, endpoint, and analytical method rather than treating a category label as a complete evidence description.
Ingredient Buyer Context
PS formulation teams can use the same review frame when comparing soy and sunflower routes, assay grades, carriers, and delivery formats. Ask whether the evidence is for the same ingredient identity and whether the proposed finished product preserves the conditions used in the study.
The source concerns the named study, company, agency, or market development. It should not be expanded into a medical treatment claim, a universal ingredient result, or a guarantee about a supplier or finished product.
Nutranexa Takeaway
The story is a research-quality signal, not a PS efficacy claim. Nutranexa supports source and document discussions for PS but does not convert third-party research into a medical promise.
For a product-specific discussion, provide the target market, application, source preference, PS grade, annual quantity, packaging, and required documents. Nutranexa can then discuss the relevant product and quality evidence without assuming facts that are not in the current controlled file.